FDA Warns of Smartwatches That Claim to Measure Glucose Levels
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, Feb. 22, 2024 -- The U.S. Food and Drug Administration has issued an advisory regarding smartwatches and smart rings that claim to track blood glucose levels.
"Sellers of these smartwatches and smart rings claim their devices measure blood glucose levels without requiring people to prick their finger or pierce the skin. They claim to use noninvasive techniques," the agency said. "These smartwatches and smart rings do not directly test blood glucose levels." No such devices have ever been approved by the agency, and trusting them can be hazardous.
"For people with diabetes, inaccurate blood glucose measurements can lead to errors in diabetes management," the agency warned. Those errors include taking the wrong doses of a drug that might send blood glucose plummeting to dangerous lows. In other cases, "taking too much of these medications can quickly lead to dangerously low glucose, leading to mental confusion, coma, or death within hours of the error," the FDA warned.
The agency said consumers are able to buy these unapproved devices easily online. "These smartwatches and smart rings are manufactured by dozens of companies and sold under multiple brand names," according to the FDA.
The FDA is asking the nation's health care providers to warn patients of this danger. "This safety communication applies to any smartwatch or smart ring that claims to measure blood glucose without piercing the skin, regardless of manufacturer or brand," the agency said.
The FDA added that it is working to prevent the illegal marketing of these devices throughout the United States.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.